A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease

Paul A. Carpenter, James Lowder, Laura Johnston, Haydar Frangoul, Hanna Khoury, Pablo Parker, Keith R. Jerome, Jeannine S. McCune, Barry Storer, Paul Martin, Frederick Appelbaum, Rafat Abonour, Peter Westervelt, Claudio Anasetti

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Results of a previous phase I study suggested that a single 3 mg/m2 dose of the humanized non-FcR-binding anti-CD3 monoclonal antibody visilizumab (Nuvion) was well tolerated and had efficacy for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). We now report results of a multicenter phase II study in which visilizumab was given to 44 participants with steroid-refractory acute GVHD. Eighty-two percent of the participants had visceral involvement, and 86% had overall grade III or IV acute GVHD at study entry. The respective complete and overall response rates were 14% and 32% at 42 days. Plasma Epstein-Barr virus DNA increased to more than 1000 copies per milliliter in 19 subjects. Seventeen received rituximab, and no fatal lymphoproliferative disorders were observed. Survival at 180 days was 32% (95% confidence interval, 18%-46%). The administration of visilizumab as used in this study seems to be sufficiently safe and effective to warrant further assessment for treatment or prevention of GVHD.

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume11
Issue number6
DOIs
StatePublished - Jun 2005

Fingerprint

Antibodies, Monoclonal, Humanized
Graft vs Host Disease
Multicenter Studies
Anti-Idiotypic Antibodies
Steroids
Lymphoproliferative Disorders
Human Herpesvirus 4
Monoclonal Antibodies
Confidence Intervals
visilizumab
DNA

Keywords

  • Anti-CD3
  • Graft-versus-host disease
  • Hematopoietic cell transplantation
  • Monoclonal antibody
  • Steroid refractory
  • Visilizumab

ASJC Scopus subject areas

  • Transplantation

Cite this

A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. / Carpenter, Paul A.; Lowder, James; Johnston, Laura; Frangoul, Haydar; Khoury, Hanna; Parker, Pablo; Jerome, Keith R.; McCune, Jeannine S.; Storer, Barry; Martin, Paul; Appelbaum, Frederick; Abonour, Rafat; Westervelt, Peter; Anasetti, Claudio.

In: Biology of Blood and Marrow Transplantation, Vol. 11, No. 6, 06.2005, p. 465-471.

Research output: Contribution to journalArticle

Carpenter, PA, Lowder, J, Johnston, L, Frangoul, H, Khoury, H, Parker, P, Jerome, KR, McCune, JS, Storer, B, Martin, P, Appelbaum, F, Abonour, R, Westervelt, P & Anasetti, C 2005, 'A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease', Biology of Blood and Marrow Transplantation, vol. 11, no. 6, pp. 465-471. https://doi.org/10.1016/j.bbmt.2005.03.002
Carpenter, Paul A. ; Lowder, James ; Johnston, Laura ; Frangoul, Haydar ; Khoury, Hanna ; Parker, Pablo ; Jerome, Keith R. ; McCune, Jeannine S. ; Storer, Barry ; Martin, Paul ; Appelbaum, Frederick ; Abonour, Rafat ; Westervelt, Peter ; Anasetti, Claudio. / A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. In: Biology of Blood and Marrow Transplantation. 2005 ; Vol. 11, No. 6. pp. 465-471.
@article{857e117173674bc78ef2f22e32a77ec2,
title = "A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease",
abstract = "Results of a previous phase I study suggested that a single 3 mg/m2 dose of the humanized non-FcR-binding anti-CD3 monoclonal antibody visilizumab (Nuvion) was well tolerated and had efficacy for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). We now report results of a multicenter phase II study in which visilizumab was given to 44 participants with steroid-refractory acute GVHD. Eighty-two percent of the participants had visceral involvement, and 86{\%} had overall grade III or IV acute GVHD at study entry. The respective complete and overall response rates were 14{\%} and 32{\%} at 42 days. Plasma Epstein-Barr virus DNA increased to more than 1000 copies per milliliter in 19 subjects. Seventeen received rituximab, and no fatal lymphoproliferative disorders were observed. Survival at 180 days was 32{\%} (95{\%} confidence interval, 18{\%}-46{\%}). The administration of visilizumab as used in this study seems to be sufficiently safe and effective to warrant further assessment for treatment or prevention of GVHD.",
keywords = "Anti-CD3, Graft-versus-host disease, Hematopoietic cell transplantation, Monoclonal antibody, Steroid refractory, Visilizumab",
author = "Carpenter, {Paul A.} and James Lowder and Laura Johnston and Haydar Frangoul and Hanna Khoury and Pablo Parker and Jerome, {Keith R.} and McCune, {Jeannine S.} and Barry Storer and Paul Martin and Frederick Appelbaum and Rafat Abonour and Peter Westervelt and Claudio Anasetti",
year = "2005",
month = "6",
doi = "10.1016/j.bbmt.2005.03.002",
language = "English",
volume = "11",
pages = "465--471",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease

AU - Carpenter, Paul A.

AU - Lowder, James

AU - Johnston, Laura

AU - Frangoul, Haydar

AU - Khoury, Hanna

AU - Parker, Pablo

AU - Jerome, Keith R.

AU - McCune, Jeannine S.

AU - Storer, Barry

AU - Martin, Paul

AU - Appelbaum, Frederick

AU - Abonour, Rafat

AU - Westervelt, Peter

AU - Anasetti, Claudio

PY - 2005/6

Y1 - 2005/6

N2 - Results of a previous phase I study suggested that a single 3 mg/m2 dose of the humanized non-FcR-binding anti-CD3 monoclonal antibody visilizumab (Nuvion) was well tolerated and had efficacy for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). We now report results of a multicenter phase II study in which visilizumab was given to 44 participants with steroid-refractory acute GVHD. Eighty-two percent of the participants had visceral involvement, and 86% had overall grade III or IV acute GVHD at study entry. The respective complete and overall response rates were 14% and 32% at 42 days. Plasma Epstein-Barr virus DNA increased to more than 1000 copies per milliliter in 19 subjects. Seventeen received rituximab, and no fatal lymphoproliferative disorders were observed. Survival at 180 days was 32% (95% confidence interval, 18%-46%). The administration of visilizumab as used in this study seems to be sufficiently safe and effective to warrant further assessment for treatment or prevention of GVHD.

AB - Results of a previous phase I study suggested that a single 3 mg/m2 dose of the humanized non-FcR-binding anti-CD3 monoclonal antibody visilizumab (Nuvion) was well tolerated and had efficacy for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). We now report results of a multicenter phase II study in which visilizumab was given to 44 participants with steroid-refractory acute GVHD. Eighty-two percent of the participants had visceral involvement, and 86% had overall grade III or IV acute GVHD at study entry. The respective complete and overall response rates were 14% and 32% at 42 days. Plasma Epstein-Barr virus DNA increased to more than 1000 copies per milliliter in 19 subjects. Seventeen received rituximab, and no fatal lymphoproliferative disorders were observed. Survival at 180 days was 32% (95% confidence interval, 18%-46%). The administration of visilizumab as used in this study seems to be sufficiently safe and effective to warrant further assessment for treatment or prevention of GVHD.

KW - Anti-CD3

KW - Graft-versus-host disease

KW - Hematopoietic cell transplantation

KW - Monoclonal antibody

KW - Steroid refractory

KW - Visilizumab

UR - http://www.scopus.com/inward/record.url?scp=19944415907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944415907&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2005.03.002

DO - 10.1016/j.bbmt.2005.03.002

M3 - Article

C2 - 15931635

AN - SCOPUS:19944415907

VL - 11

SP - 465

EP - 471

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -